A Phase 3 interventional study of AMARGOL® in Digestive System Disorders, sponsored by Laboratorio Saude Ltda.. Completed at 1 site in Brazil. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-12-06.
Sponsored by Laboratorio Saude Ltda. · Phase 3, Interventional, and Treatment
This is a Phase 3: Efficacy Study for AMARGOL® a phytomedicine used for asymptomatic digestive complaints.
This study will be performed for proving the efficacy of AMARGOL®, a phytomedicine product, under the Brazilian law for registration and revalidation RDC 14/2010.
AMARGOL® indications are for non specific digestive complaints as laxative and anti-dyspeptic.
Is a mixture of 7 plant extracts: Aloe ferox, Angelica archangelica, Alpinia officinarum, Cinnamomum zeylanicum, Gentiana lutea, Commiphora myrrh and Rheum palmatum.
Placebo controlled test
615 studies on the registry are indexed under Digestive System Diseases; 114 are open to participants now.
This study's enrollment of 60 is below the median of 80 across 402 interventional studies indexed under Digestive System Diseases.
Browse Digestive System Diseases studies →This is the only study on the registry with Laboratorio Saude Ltda. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
per oral solution 40 mL single dose
Drug: AMARGOL®
per oral solution 40 mL single dose
Drug: AMARGOL®
per oral solution, 40 mL single dose
Also known as: AMARGOL, Phytomedicine, Herbal Extracts Mixture
VAS - visual analogue scale
Single dose 40mL AMARGOL 20 minutes before Dinner - strong meal
Time frame: 24h
This study is completed, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.